Genetic of Skeletal Muscle Insulin Resistance
ConditionInsulin Stimulated
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe University of Texas Health Science Center at San Antonio
About this trial
In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Males and Females Age 18-75
Body Mass Index (BMI) > 18
Hemoglobin A1c < 5.7
Creatinine < 2
Disqualifiers
Urine albumin excretion>300mg/day
Partial thromboplastin time (PTT) >35International normalized ratio (INR) > 1.2
No oral corticosteroids for 1 month
No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months
Trial design
Design model
Single group
Treatments tested in this trial
Insulin 80mU/m2*min
Other intervention80mU/m2\*min euglycemic-hyperinsulinemic clamp
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Insulin stimulatedExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Cell type specific quantitative trait loci in skeletal muscle
Single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) will be used to reveal cell type-specific molecular response quantitative trait loci (QTLs) acutely regulated by insulin signaling and glucose uptake
Time frame
Before and after insulin clamp (Baseline to approximately 6 hours)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The University of Texas Health Science Center at San Antonio
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov